491 results on '"Sandhaus, Robert"'
Search Results
2. Clinical trial attitudes among individuals with Alpha-1 antitrypsin deficiency
3. Pathogenic Mutations Conferring α1-Antitrypsin Deficiency Are Identified Accurately by a Novel Multiplexed Molecular Assay
4. Long-Term SGRQ Stability in a Cohort of Individuals with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
5. A multicenter study to evaluate pulmonary function in osteogenesis imperfecta
6. Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19
7. Author Correction: Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19
8. Analysis of alpha‐1‐antitrypsin (AAT)‐regulated, glucocorticoid receptor‐dependent genes in macrophages reveals a novel host defense function of AAT.
9. The Inhibition of Serine Proteases by Serpins Is Augmented by Negatively Charged Heparin: A Concise Review of Some Clinically Relevant Interactions
10. Prevalence of Cardiovascular Disease and Rate of Major Adverse Cardiovascular Events in Severe Alpha-1 Antitrypsin Deficiency COPD
11. A 28-day clinical trial of aerosolized hyaluronan in alpha-1 antiprotease deficiency COPD using desmosine as a surrogate marker for drug efficacy
12. Limitations and Challenges of Conducting Budget Impact Analyses in Rare Diseases: A Case Study of Alpha-1 Antitrypsin Deficiency
13. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult.
14. Health-related Quality of Life in Alpha-1 Antitrypsin Deficiency–associated Chronic Obstructive Pulmonary Disease
15. Alpha-1 antitrypsin inhibits fractalkine-mediated monocyte-lung endothelial cell interactions
16. Managing the Alpha-1 patient in the ICU: Adapting broad critical care strategies in AATD
17. Diagnostic evaluation of bronchiectasis
18. Lung Disease of Alpha-1 Antitrypsin Deficiency
19. Genotype is associated with smoking and other key health behaviors among individuals with alpha-1 antitrypsin deficiency-associated lung disease
20. Respiratory impairment impacts QOL in osteogenesis imperfecta independent of skeletal abnormalities
21. Alpha-1-antitrypsin antagonizes COVID-19: a review of the epidemiology, molecular mechanisms, and clinical evidence
22. Cardiopulmonary Status in Adults with Osteogenesis Imperfecta: Intrinsic Lung Disease May Contribute More Than Scoliosis
23. Environmental, Occupational, and Genetic Risk Factors for α-1 Antitrypsin Deficiency
24. Detection of alpha-1 antitrypsin deficiency: the past, present and future
25. A Hybrid Effectiveness/Implementation Clinical Trial of Adherence to Long-Term Oxygen Therapy for Chronic Obstructive Pulmonary Disease.
26. Impact of Coronavirus Disease 2019 and Vaccination Attitudes on Alpha-1 Antitrypsin Deficiency
27. Quality of Life and Mortality Outcomes for Augmentation Naïve and Augmented Patients with Severe Alpha-1 Antitrypsin Deficiency
28. Augmentation Therapy for Alpha-1 Antitrypsin Deficiency: Patient Experiences With Self-Infusion, Home Providers, and Clinics
29. Scoliosis and Cardiopulmonary Outcomes in Osteogenesis Imperfecta Patients
30. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial
31. α1-Antitrypsin Binds to the Glucocorticoid Receptor with Anti-Inflammatory and Antimycobacterial Significance in Macrophages
32. A NOVEL PREDICTIVE MODEL USING REAL-WORLD DATA TO IMPROVE DIAGNOSIS OF ALPHA-1 ANTITRYPSIN DEFICIENCY AMONG PATIENTS WITH COPD
33. Historical Perspective
34. List of Contributors
35. Quantitative disease progression model of α‐1 proteinase inhibitor therapy on computed tomography lung density in patients with α‐1 antitrypsin deficiency
36. Alpha-1-antitrypsin antagonizes COVID-19: a review of the epidemiology, molecular mechanisms, and clinical evidence.
37. Patient Involvement in the Design of a Patient-Centered Clinical Trial to Promote Adherence to Supplemental Oxygen Therapy in COPD
38. Comparative Effectiveness of Peer-Led Supplemental O2 Infoline for Patients and Caregivers (PELICAN)
39. The Social Environment and Illness Uncertainty in Chronic Obstructive Pulmonary Disease
40. Alpha-1-antitrypsin binds to the glucocorticoid receptor with biological significance in macrophages
41. Patient-Reported Pulmonary Symptoms, Exacerbations, and Management in a Cohort of Patients With Alpha-1 Antitrypsin Deficiency
42. Lung Disease of Alpha-1 Antitrypsin Deficiency
43. Clinical and Preclinical Studies with Low-Clearance Liposomal Amikacin (MiKasome®)
44. Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic
45. PATIENT-REPORTED ASSESSMENTS OF A NOVEL, CLOSED-SYSTEM HEATED HUMIDIFICATION DEVICE FOR INDIVIDUALS WITH COPD REQUIRING SUPPLEMENTAL OXYGEN AT HOME: THE O2ASIS COMFORT TRIAL
46. PATIENT-REPORTED PULMONARY SYMPTOMS AND EXACERBATIONS IN A COHORT OF PATIENTS WITH ALPHA-1 ANTITRYPSIN DEFICIENCY
47. The impact of age on outcomes in chronic obstructive pulmonary disease differs by relationship status
48. Human treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression
49. Might your respiratory patient have alpha-1 antitrypsin deficiency?
50. Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis Study. Alpha-1 Protocol
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.